InSilicoTrials uses computational models and AI technology to accelerate the development of new drugs, reduce and refine tests on animals and clinical trials, improve the safety of medical products, and cut R&D costs.

InSilicoTrials

Qualitest is an AI-led quality engineering company that specializes in software testing solutions across various industries. Self-described as a leader in continuous testing and quality engineering, it offers a range of services including quality assurance, quality engineering, and digital engineering.

Qualitest

We are a game-changer in the life sciences sector. Our mission is to hyper-accelerate drug and medical device development leveraging top notch technology like Modeling and Simulation and Artificial Intelligence.

We are an international team of professionals coming from healthcare, regulatory, engineering simulation, IT, cloud, and cybersecurity.

We work with a network of 70+ prestigious universities and research centers worldwide and we are currently part of 5 EU-funded projects that are really making a difference in healthcare: SimCardioTest, Brainteaser, In Silico World, Disc4All and TranSys.

Our unique cloud platform offers Pharma and MedTech companies state-of-the-art simulation tools that can highly reduce the cost and time of medical products development, while increasing their safety and efficacy. We are endorsed by top international regulators such as FDA and EMA., that have been encouraging for years the adoption of in silico methods in healthcare.

We share a vision: to deeply innovate the healthcare industry through state-of-the-art technology, which means less tests on humans and animals, and more treatments, new medicines and safer medical products for millions of people worldwide. 

Live longer, live better.

United Ventures

Pi Campus

StartUp Health

𝗔𝘀 𝘄𝗲 𝗲𝗺𝗯𝗿𝗮𝗰𝗲 𝘁𝗵𝗲 𝘄𝗮𝗿𝗺𝘁𝗵 𝗼𝗳 𝘀𝘂𝗺𝗺𝗲𝗿, 𝗶𝘁'𝘀 𝘁𝗶𝗺𝗲 𝗳𝗼𝗿 𝗮 𝘄𝗲𝗹𝗹-𝗱𝗲𝘀𝗲𝗿𝘃𝗲𝗱 𝗯𝗿𝗲𝗮𝗸!
Our team at InSilicoTrials will be taking some time off to recharge and come back with fresh energy and innovative ideas. We're excited about the future and the continued evolution of our work in 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 technology.

𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝘂𝗽𝗱𝗮𝘁𝗲𝘀, 𝗮𝘀 𝘄𝗲 𝗿𝗲𝘁𝘂𝗿𝗻 𝗿𝗲𝗳𝗿𝗲𝘀𝗵𝗲𝗱 𝗮𝗻𝗱 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗼𝗻 𝗻𝗲𝘄 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀.

Looking for some engaging summer reading? Check out 𝗚𝗼𝗼𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 (𝗚𝗦𝗣), a book we co-edited on standardizing simulation practices. It’s a must-read for anyone interested in the credibility and advancement of 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 models in drug development. 
Discover more about GSP here: https://lnkd.in/d8ch_7Ys

Wishing everyone a fantastic summer! 🌴

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁: 𝗙𝗗𝗔 𝗮𝗻𝗱 𝙄𝙣 𝙎𝙞𝙡𝙞𝙘𝙤 𝗧𝗿𝗶𝗮𝗹𝘀

The FDA is setting new standards in drug development with 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 trials, and we're proud to be at the forefront of this revolution! Luca Emili, CEO of InSilicoTrials, recently shared key insights during a workshop co-hosted by the FDA and the Clinical Trial Transformation Initiative (CTTI):

• 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: The FDA is advancing AI Regulatory Science to streamline drug development, with over 300 AI-based submissions under review.
• 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: Luca emphasized how integrating AI with traditional modeling, including virtual patients, reduces costs, speeds up trials, and addresses ethical concerns.
• 𝗠𝗼𝗱𝗲𝗹 𝗧𝗿𝘂𝘀𝘁, 𝗧𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆, 𝗮𝗻𝗱 𝗘𝘅𝗽𝗹𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆: 𝘐𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 models must be transparent and explainable to gain trust and ensure their effectiveness. Luca discussed the importance of making AI models not just perform well, but also understandable and interpretable, so stakeholders can confidently rely on them for critical decisions.
• 𝗚𝗼𝗼𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 (𝗚𝗦𝗣): The adoption of the GSP framework, as highlighted by Luca, is crucial for standardizing simulation practices and ensuring the credibility and trustworthiness of in silico models in drug development. Discover more about GSP here: https://lnkd.in/d8ch_7Ys
• 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗮𝗻𝗱 𝗘𝘁𝗵𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: By minimizing the need for real patient data and animal testing, 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 trials are making drug development more accessible and ethical.

For those invested in the future of healthcare, this article is a must-read. We're excited to see how the work led by Luca and our team at InSilicoTrials is helping shape the future of personalized and innovative treatments! 🌟


#InSilicoTrials #DrugDevelopment #AIinHealthcare #HealthcareInnovation #RegulatoryScience #ClinicalTrials #DigitalHealth #FDA #AI #VirtualPatients #EthicalInnovation #HealthcareRevolution

𝗙𝗗𝗔 𝗖𝗧𝗧𝗜 𝗔𝗜 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽:
𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗔𝗜 𝗮𝗻𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻: 𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗶𝘀 𝗡𝗼𝘄

🌐At InSilicoTrials, we are 𝗿𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗯𝘆 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗔𝗜 𝘄𝗶𝘁𝗵 𝗿𝗼𝗯𝘂𝘀𝘁 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗺𝗼𝗱𝗲𝗹𝘀 𝗮𝗻𝗱 𝘃𝗶𝗿𝘁𝘂𝗮𝗹 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. Our CEO and Founder, Luca Emili was invited to speak on a panel with Michael Lingzhi Li (Harvard Business School) and Subha Madhavan (Pfizer). Luca shared the In Silico approach combining a rich library of validated models, an ecosystem of 70+ partners, and AI that accelerates data strategies while adhering to Good Simulation Practices (GSP). 

📗 𝗚𝗼𝗼𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲 (𝗚𝗦𝗣):Co-published as a best practice framework for in silico methods, GSP is the cornerstone of reliable, transparent, and explainable use of simulation in drug development. During the discussion there was many citation to the book that alongside the GMLP is going to support effort in this field and forge the next generation of tech bio scientists. Developed in collaboration with IST, the FDA, VPHi, In Silico World, Avicenna Alliance and over 130 academic and industry experts, this framework turns policy into practice, ensuring that use of simulation in R&D is not only innovative but also safe and trustworthy. 
Download your free copy ▶ https://lnkd.in/d8ch_7Ys

✨ 𝗔𝗜 𝗶𝗻 𝗔𝗰𝘁𝗶𝗼𝗻 We're excited to present our latest use case, which leverages AI to accelerate the FDA Diversity Action Plan. By automating literature review, we reduce months of work to mere minutes, paving the way for more inclusive and efficient drug development processes.

🔍 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 "𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗜”:This new term encapsulates the essence of model explainability, reliability, and transparency. It’s about building confidence in AI that meets medical-grade standards, offering clear guidance on expected outcomes and ensuring ethical and economic considerations are at the forefront.

𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗶𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻, 𝗿𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗯𝘆 𝗗𝗲𝘀𝗶𝗴𝗻 𝗯𝘆 𝟵𝟬%. With our trusted AI models, we’re entering a new era of safer drug development.
 
Join us on this journey to a future where AI-driven innovation ensures better patient outcomes, faster development timelines, and greater confidence in every step of the process. 🌐
 
#AIinHealthcare #GoodSimulationPractice #DrugDevelopment #InSilicoTrials #MedicalAI #ClinicalResearch #Innovation

As we approach the summer break, we're thrilled to share some 𝐤𝐞𝐲 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟒 In Silico World 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 — a project we are part of:

 🔸 The 𝐈𝐧 𝐒𝐢𝐥𝐢𝐜𝐨 𝐖𝐨𝐫𝐥𝐝 𝐅𝐢𝐧𝐚𝐥 𝐄𝐯𝐞𝐧𝐭 will take place at VPH2024 in Stuttgart from September 4-6.
 🔸 The “𝐓𝐨𝐰𝐚𝐫𝐝 𝐆𝐨𝐨𝐝 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐞” book is now freely available to the entire in silico medicine community. 
 🔸 Don’t miss 𝐕𝐏𝐇𝟐𝟎𝟐𝟒 — where scientific excellence and collaboration take center stage.
 
👇 Stay connected and explore more about In Silico World Consortium by clicking the link below!

https://bit.ly/3WJbGuD

#InSilicoWorld #newsletter #InSilicoTrials #healthcareinnovation #healthcare #insilico #modelingandsimulation

Reminder: Today is the day! 
The hybrid public workshop on 𝘼𝙧𝙩𝙞𝙛𝙞𝙘𝙞𝙖𝙡 𝙄𝙣𝙩𝙚𝙡𝙡𝙞𝙜𝙚𝙣𝙘𝙚 𝙞𝙣 𝘿𝙧𝙪𝙜 & 𝘽𝙞𝙤𝙡𝙤𝙜𝙞𝙘𝙖𝙡 𝙋𝙧𝙤𝙙𝙪𝙘𝙩 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩, hosted by the FDA and Clinical Trials Transformation Initiative (CTTI), starts at 10 AM EDT (4 PM CET).

Our CEO, Luca Emili, will be discussing 𝙈𝙤𝙙𝙚𝙡 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚, 𝙀𝙭𝙥𝙡𝙖𝙞𝙣𝙖𝙗𝙞𝙡𝙞𝙩𝙮, 𝙖𝙣𝙙 𝙏𝙧𝙖𝙣𝙨𝙥𝙖𝙧𝙚𝙣𝙘𝙮 in Session 3. It's a great opportunity to gain insights from leading experts and explore the future of #AI in #drugdevelopment. 

✍ Registration is still open: https://lnkd.in/ecWC8iAF

Sharing the 4th episode of the #DigitalTwin Theory podcast with our community: "Virtual Patients: Exploring the World of In Silico Trials", featuring Professor Francesco Pappalardo from the Università di Catania.

Discover how #virtualpatients and #insilicotrials can make #drugdevelopment faster, cheaper, and safer. This episode explores the potential to revolutionize #clinical trials, reducing the 10-15 year timeline and high costs associated with bringing a drug to market.
 
🎧 Tune in to learn more about the future of #pharmaceuticals and the role of #digitaltwins!

𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗘𝗖𝗖𝗣𝗠 𝗙𝗼𝗿𝘂𝗺 𝟮𝟬𝟮𝟰
🗓 September 11-12, 2024 | University of Technology Graz, Austria

We are excited to announce that our CEO Luca Emili will be speaking at the #ECCPMForum2024 organized by our partner RCPE - Research Center Pharmaceutical Engineering GmbH. The event unites global leaders in #pharmaceutical research to explore the latest advancements in continuous #manufacturing and #digitalinnovation.

Our CEO's presentation, titled 𝙃𝙮𝙥𝙚𝙧 𝘼𝙘𝙘𝙚𝙡𝙚𝙧𝙖𝙩𝙚 𝙍&𝘿 𝙬𝙞𝙩𝙝 𝙄𝙣 𝙎𝙞𝙡𝙞𝙘𝙤 𝙏𝙧𝙞𝙖𝙡𝙨, will take place on September 12. It will focus on the transformative role of #modelingandsimulation in accelerating R&D, optimizing efficiency, and reducing costs within the #pharmaceutical industry.

Highlights of #ECCPMForum2024:
🔸 Engage with #industry leaders and experts
🔸 Discover pioneering technologies in #drugdevelopment
🔸 Participate in hands-on #workshops and discussions
🔸 #Network with key players in #pharmaceuticalresearch

✍ Registration: https://eccpm.com/forum24/

𝐌𝐚𝐫𝐤 𝐭𝐡𝐞 𝐃𝐚𝐭𝐞: 𝟏 𝐀𝐮𝐠𝐮𝐬𝐭 𝐒𝐞𝐞𝐬 𝐭𝐡𝐞 𝐄𝐔 𝐀𝐈 𝐀𝐜𝐭 𝐄𝐧𝐭𝐞𝐫 𝐈𝐧𝐭𝐨 𝐅𝐨𝐫𝐜𝐞

Today marks the entry into force of the #EUAIAct, the first comprehensive legal framework for #artificialintelligence in the world. This landmark regulation aims to ensure AI systems in the EU are safe, transparent, and respectful of fundamental rights.

𝗞𝗲𝘆 𝗣𝗼𝗶𝗻𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 #EUAIAct

✅ Risk-Based Classification
✅ Prohibition of Harmful AI 
✅ Stringent Requirements for High-Risk AI
✅ Transparency for Limited-Risk AI
✅ Encouragement for Innovation
✅ Alignment with European Values

The #EUAIAct sets a global standard for #AIregulation, ensuring that #technological advancement aligns with #ethical principles and #societal values.

🔗 Learn more about the #EUAIAct and its implications: https://lnkd.in/ehhaxR9

#EUAIAct #AIRegulation #EthicalAI #Innovation #AI

Excited to announce that our CEO Emili will be speaking at the FDA / CTTI 𝗣𝘂𝗯𝗹𝗶𝗰 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗼𝗻 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗶𝗻 𝗗𝗿𝘂𝗴 & 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 
🗓️ August 6, 2024 | 10:00 AM - 5:30 PM EDT
📍 FDA Great Room, 10903 New Hampshire Ave., Silver Spring, MD, 20993 (also available via Zoom)
 
Learn from experts discussing responsible #AI use in #drugdevelopment, real case examples, and future considerations.
 
𝗔𝗴𝗲𝗻𝗱𝗮 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

🔹 𝗢𝗽𝗲𝗻𝗶𝗻𝗴 𝗥𝗲𝗺𝗮𝗿𝗸𝘀: Morgan Hanger (Clinical Trials Transformation Initiative (CTTI))
🔹 𝗞𝗲𝘆𝗻𝗼𝘁𝗲: Patrizia Cavazzoni (FDA)
🔹 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝟭: Optimizing AI Model Design with Elazer Edelman (MIT), Sam Glassenberg (Level Ex), and Charles Fisher (Unlearn.AI). Moderated by 
Tala Fakhouri (FDA) & Anindita (Annie) Saha (FDA).
🔹 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝟮: Tackling Data Challenges with Ittai Dayan MD (Rhino Health), Merage Ghane (ideas42), and Wade Davis (Moderna). Moderated by
Stephen Pyke (Parexel) & Marsha Samson (FDA)
🔹 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝟯: AI Model Performance and Transparency featuring our CEO Luca Emili, Michael Lingzhi Li (Harvard Business School), and Subha Madhavan (Pfizer). The session will tackle challenges in #AI for #drug development, focusing on #model performance, explainability, and transparency & discussing strategies for integrating #human decision-making (“human in the loop”). Moderated by Hussein Ezzeldin (FDA) & Artem A. Trotsyuk (Stanford University)
🔹𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝟰: Addressing Gaps in AI Use with Dina Katabi (MIT), Andrew Bate (GSK), Ryan Hoshi Ph.D. (AbbVie), and Nicole Mahoney (Novartis). Moderated by Tala Fakhouri & Scott Steele (FDA)
🔹 𝗤&𝗔 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 with Hesha Jani Duggirala (FDA), Stephen Pyke & Qi Liu
🔹 𝗖𝗼𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗥𝗲𝗺𝗮𝗿𝗸𝘀 : Jacqueline Corrigan-Curay (FDA)

Get in touch if interested in joining the executive roundtable we're organizing following the event with focus on #InSilicoTechnologies' benefits and a preview of a new #regulatory #educationforum.
 
👉Check the final agenda and register: https://lnkd.in/eUFB2nCD

Thank you, Moonstone Venture Capital, for recognizing our innovative work. 

We're honored to be part of your portfolio and appreciate your support in highlighting our efforts to revolutionize drug development.

Metric
Company Name	InSilicoTrials	Qualitest
Symbol
MSH ID	COM:INSILICOTRIALS	COM:QAINFOTECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Commercial & Professional Services
Industry	Biotechnology	Technology
Country	IT	US
Stage
Employee Count
Website	insilicotrials.com	qainfotech.com
LinkedIn	insilicotrials
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

INSI

COM:INSILICOTRIALS

InSilicoTrials

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue